Latest news with #GMyrbetriq
Business Upturn
a day ago
- Business
- Business Upturn
Zydus shares in focus after US Court rejects plea in Astellas Patent case
Zydus shares were in focus after a US District Court reportedly rejected the proposal by generic firms (Zydus & Lupin) in a patent interpretation case against Astellas concerning the '189 patent. As of 9:39 AM, the shares were trading 1.21% lower at Rs 967.00. The litigation involves the key drug G Myrbetriq. Zydus shares opened at ₹968.10, touched a high of ₹975.00 and a low of ₹960.00 during the session. The stock's 52-week high stands at ₹1,324.30, while the 52-week low is ₹795.00. Zydus Wellness Q4FY25 Results Zydus Wellness Limited has reported a strong financial performance for the quarter and year ended March 31, 2025. In Q4FY25, the company's revenue grew 17.1% year-on-year to ₹910.6 crore, up from ₹778 crore in the same quarter last year. Net profit for the quarter also saw a healthy rise of 14.3% YoY, reaching ₹171.9 crore compared to ₹150.3 crore in Q4FY24. For the full year FY25, Zydus Wellness posted revenue of ₹2,691.2 crore, marking an increase from ₹2,315.2 crore in FY24. Net profit for the year stood at ₹346.9 crore, up significantly from ₹266.9 crore in the previous year. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
a day ago
- Business
- Business Upturn
Lupin shares in focus after US Court rejects plea in Astellas Patent case
Lupin shares were in focus after a U.S. District Court rejected the proposal filed by generic firms (Zydus & Lupin) in a legal dispute with Astellas Pharma over the interpretation of the '189 patent. The case pertains to the key urology drug G Myrbetriq (mirabegron), used to treat overactive bladder. The court's decision is seen as a setback for generic challengers seeking to enter the market with versions of the drug ahead of patent expiry. Lupin's stock opened at ₹1,998.00, touched a high of ₹2,012.90 and a low of ₹1,980.00 during the session. The stock's 52-week high stands at ₹2,402.90, while the 52-week low is ₹1,543.00. As of 9:51 AM, the shares were trading 0.59% lower at Rs 2,011.20. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
